A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma

Trial Profile

A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 May 2017

At a glance

  • Drugs Durvalumab (Primary) ; Lenalidomide (Primary)
  • Indications Cutaneous T cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Feb 2017 Planned primary completion date changed from 1 Jan 2020 to 1 Sep 2019.
    • 14 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 10 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top